Zoetis (ZTS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this animal health company have returned +0.7% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical - Drugs industry, to which Zoetis belongs, has gained 0.1% over this period. Now the key question is: Where could the stock be headed in the near term?Although ...

Core Insights - Zoetis, Inc. reported first-quarter 2023 adjusted earnings of $1.38 per share, exceeding the Zacks Consensus Estimate of $1.34 and up from $1.31 in the same quarter last year [1] - Total revenues for the quarter increased by 10% year over year to $2.19 billion, surpassing the Zacks Consensus Estimate of $2.14 billion [1] Quarterly Highlights - The U.S. segment revenues rose 16% year over year to $1.16 billion, beating the Zacks Consensus Estimate of $1.1 billion [3] - Companion animal product sales in the U.S. surged 25%, driven by monoclonal antibody products for osteoarthritis pain and other key dermatology products [3] - International segment revenues grew 3% year over year to $1.007 billion but fell short of the Zacks Consensus Estimate of $1.026 billion [4] Product Performance - Livestock product sales declined by 7% in the reported quarter, primarily due to lower cattle product sales [4] - Companion animal product sales in the international segment increased by 10% on a reported basis, driven by growth in key products [4] - Livestock product sales decreased 4% year over year on a reported basis but grew 2% operationally, with price increases contributing to growth in cattle and poultry portfolios [5] 2024 Guidance - Zoetis has lowered its 2024 adjusted earnings guidance to a range of $5.71-$5.81 per share from the previous $5.74-$5.84 [7] - Projected revenues for 2024 are between $9.05 billion and $9.2 billion, indicating operational growth of 8.5-10.5% [7] Strategic Developments - In April 2024, Zoetis announced a definitive agreement to divest its medicated feed additive product portfolio for $350 million to Phibro Animal Health, aligning with its capital allocation strategy [9] - The divestment aims to focus investments on animal health solutions, productivity, and sustainability [9]

Zoetis Inc (NYSE:ZTS) Q1 2024 Results Conference Call May 2, 2024 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley David Westenberg - Piper Sandler Brandon Vazquez - William Blair Christopher LoBianco - TD Cowen Nathan Rich - Goldman Sachs Balaji Prasad - Barclays Glen Santangelo - Jeffe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number:001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 46-069 ...

Zoetis (ZTS) reported $2.19 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.5%. EPS of $1.38 for the same period compares to $1.31 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.14 billion, representing a surprise of +2.36%. The company delivered an EPS surprise of +2.99%, with the consensus EPS estimate being $1.34.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Zoetis (ZTS) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.34 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.99%. A quarter ago, it was expected that this animal health company would post earnings of $1.33 per share when it actually produced earnings of $1.24, delivering a surprise of -6.77%.Over the last four quarters, the compa ...

EXHIBIT 99.1 Zoetis Announces First Quarter 2024 Results • Reports Revenue of $2.2 Billion, Growing 10%, and Net Income of $599 Million, or $1.31 per Diluted Share, Increasing 9% and 10%, Respectively, on a Reported Basis for First Quarter 2024 • Delivers 12% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for First Quarter 2024 • Reports Adjusted Net Income of $634 Million, or Adjusted Diluted EPS of $1.38, for First Quarter 2024 • Updates Full Year 2024 Revenue Guidance to ...

Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.35 per share in its upcoming release, pointing to a year-over-year increase of 3.1%. It is anticipated that revenues will amount to $2.14 billion, exhibiting an increase of 7% compared to the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their i ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Zoetis (ZTS) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Zoetis currently has an average brok ...

In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day. This change lagged the S&P 500's daily gain of 0.87%. At the same time, the Dow added 0.67%, and the tech-heavy Nasdaq gained 1.11%.Shares of the animal health company have depreciated by 13.26% over the course of the past month, underperforming the Medical sector's loss of 6.67% and the S&P 500's loss of 3.97%.Market participants will be closely following the financial results of Zoetis in its upcomi ...